Figure 1

PF-3845 treatment reduces anxiety-like behaviors in the light–dark box and NIH assay. PF-3845 (maroon bars) reverses stress-induced anxiety in the light–dark box as compared with vehicle treatment (white bars) as measured by (a) distance traveled in the light zone as a percent of total distance traveled, (b) time in the light zone and (c) total number of light-zone entries. (d) PF-3845 also reverses the stress-induced increase in latency to first drink in the NIH assay (e) without affecting total food consumption (f). (g) Pharmacological blockade of CB1 receptors via rimonabant treatment (R, white bars) prevents PF-3845 (maroon bars) from reversing stress effects on latency in the NIH assay. (h) PF-3845 does not significantly alter consumption in the NIH assay with rimonabant co-treatment. *P<0.05, **P<0.01, ***P<0.001 significantly different from vehicle. NIH, novelty-induced hypophagia.